Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Print ISSN: 1007-9327 (Print) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
    • Publication Information:
      Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
      Original Publication: Beijing : WJG Press, c1998-
    • Subject Terms:
      Apoptosis* ; Neovascularization, Pathologic*; Phosphoric Monoester Hydrolases/*genetics ; Stomach Neoplasms/*blood supply ; Stomach Neoplasms/*pathology ; Tumor Suppressor Proteins/*genetics; Adult ; Aged ; Aged, 80 and over ; Caspase 3 ; Caspases/metabolism ; Cell Differentiation ; Female ; Gastric Mucosa/metabolism ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness ; PTEN Phosphohydrolase ; Phosphoric Monoester Hydrolases/metabolism ; Stomach Neoplasms/physiopathology ; Stomach Neoplasms/secondary ; Tumor Suppressor Proteins/metabolism
    • Abstract:
      Aim: To investigate expression of PTEN in gastric cancer and to explore its roles in tumorigenesis and progression of gastric cancer.
      Methods: Formalin-fixed and paraffin-embedded tissues of adjacent non-tumor mucosa and primary foci from 113 cases of gastric cancers were studied for the expression of PTEN and Caspase-3 and microvessel density (MVD) by streptavidin-peroxidase (S-P) immunohistochemistry with antibodies against PTEN, Caspase-3, and CD34. The relationship between PTEN and Caspase 3 expression and clinicopathological parameters of tumors was compared.
      Results: Primary gastric cancer cells expressed PTEN less frequently than adjacent epithelial cells of primary foci (54.9 % vs 89.4 %; P=0.000, chi(2)=33.474). PTEN expression was significantly associated with invasive depth (P=0.003, rs=0.274), metastasis (P=0.036, rs=0.197), growth pattern (P=0.008, rs=0.282), Lauren's classification (P=0.000, rs=0.345), and histological classification (P=0.005, rs=0.262) of tumors, but not with tumor size (P=0.639, rs=0.045), Borrmann's classification (P=0.544, rs=0.070) or TNM staging (P=0.172, rs=0.129). PTEN expression was negatively correlated with MDV in primary gastric cancer (P=0.020, F=5.558). Primary gastric cancer cells showed less frequent immunoreactivity to Caspase-3 than adjacent epithelial cells of primary foci (32.7 % vs 50.4 %; P=0.007, chi(2)=7.286). Caspase-3 expression was dependent of PTEN expression in primary gastric cancer cells (P=0.000, chi(2)=15.266).
      Conclusion: Down-regulated expression of PTEN plays an important role in tumorigenesis, progression, growth, differentiation and angiogenesis of gastric cancer. Low expression of PTEN can decrease expression of Caspase-3 to disorder apoptosis of tumor cells, which might explain the molecular mechanisms of PTEN contributions to tumorigenesis and progression of gastric cancer.
    • References:
      Annu Rev Biochem. 2001;70:247-79. (PMID: 11395408)
      J Exp Med. 2002 Aug 5;196 (3):335-48. (PMID: 12163562)
      Int J Cancer. 2001 Jan 15;91(2):219-24. (PMID: 11146448)
      Am J Hum Genet. 2002 Apr;70(4):829-44. (PMID: 11875759)
      J Biol Chem. 2001 Sep 21;276(38):35786-93. (PMID: 11448956)
      J Biol Chem. 2002 Mar 29;277(13):10760-6. (PMID: 11784722)
      J Natl Cancer Inst. 1999 Nov 3;91(21):1820-8. (PMID: 10547389)
      Oncogene. 1999 Jul 8;18(27):3936-43. (PMID: 10435616)
      Nat Genet. 1997 Apr;15(4):356-62. (PMID: 9090379)
      Clin Cancer Res. 2001 Sep;7(9):2636-42. (PMID: 11555573)
      Neuro Oncol. 1999 Apr;1(2):124-37. (PMID: 11550308)
      Oncol Res. 2000;12(1):33-41. (PMID: 11061344)
      Eur J Biochem. 1999 Aug;263(3):605-11. (PMID: 10469123)
      Science. 1998 Nov 6;282(5391):1027,1029-30. (PMID: 9841444)
      Oncogene. 2001 Oct 11;20(46):6669-78. (PMID: 11709701)
      Cancer Res. 1999 Apr 1;59(7):1449-53. (PMID: 10197612)
      Cancer Res. 1997 Apr 15;57(8):1605-13. (PMID: 9108467)
      J Clin Pathol. 2001 May;54(5):367-70. (PMID: 11328835)
      J Cell Biol. 1998 Nov 30;143(5):1375-83. (PMID: 9832564)
      Front Biosci. 2002 May 01;7:e245-51. (PMID: 11991859)
      Cancer Invest. 1999;17(6):441-7. (PMID: 10434955)
      J Neurosurg. 2001 Oct;95(4):651-9. (PMID: 11596960)
      Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1749-53. (PMID: 10677529)
      Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5. (PMID: 10200246)
      Anticancer Res. 2001 Nov-Dec;21(6B):4207-19. (PMID: 11908674)
      Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12 ):1441-5. (PMID: 11735811)
      Cancer Res. 1999 Sep 1;59(17 ):4291-6. (PMID: 10485474)
      Cancer Res. 1999 Jan 15;59(2):442-9. (PMID: 9927060)
      World J Gastroenterol. 2001 Feb;7(1):53-9. (PMID: 11819733)
      Mol Cell. 2000 Oct;6(4):851-60. (PMID: 11090623)
      J Korean Med Sci. 1999 Jun;14(3):263-70. (PMID: 10402168)
      Proc Natl Acad Sci U S A. 2001 Aug 28;98 (18):10031-3. (PMID: 11526226)
      Lancet Oncol. 2001 Sep;2(9):533-43. (PMID: 11905707)
      Neurosurg Rev. 2001 Jul;24(2-3):97-102. (PMID: 11485247)
      Int J Cancer. 2000 Nov 15;88(4):620-5. (PMID: 11058880)
      Int J Cancer. 2001 Jan 1;91(1):22-6. (PMID: 11149415)
      J Biol Chem. 1998 May 29;273(22):13375-8. (PMID: 9593664)
    • Accession Number:
      0 (Tumor Suppressor Proteins)
      EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
      EC 3.1.3.67 (PTEN Phosphohydrolase)
      EC 3.1.3.67 (PTEN protein, human)
      EC 3.4.22.- (CASP3 protein, human)
      EC 3.4.22.- (Caspase 3)
      EC 3.4.22.- (Caspases)
    • Publication Date:
      Date Created: 20030815 Date Completed: 20030924 Latest Revision: 20220310
    • Publication Date:
      20221213
    • Accession Number:
      PMC4611520
    • Accession Number:
      10.3748/wjg.v9.i8.1662
    • Accession Number:
      12918097